| 000 | 01606 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515004833.0 | ||
| 264 | 0 | _c20060302 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/CIRCULATIONAHA.104.523324 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFries, Roland | |
| 245 | 0 | 0 |
_aSildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. _h[electronic resource] |
| 260 |
_bCirculation _cNov 2005 |
||
| 300 |
_a2980-5 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBlood Flow Velocity _xdrug effects |
| 650 | 0 | 4 |
_aConnective Tissue Diseases _xcomplications |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aPiperazines _xadverse effects |
| 650 | 0 | 4 | _aPurines |
| 650 | 0 | 4 |
_aRaynaud Disease _xdrug therapy |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xcomplications |
| 650 | 0 | 4 | _aSildenafil Citrate |
| 650 | 0 | 4 | _aSulfones |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVasodilation |
| 650 | 0 | 4 |
_aVasodilator Agents _xadverse effects |
| 700 | 1 | _aShariat, Kaveh | |
| 700 | 1 | _avon Wilmowsky, Hubertus | |
| 700 | 1 | _aBöhm, Michael | |
| 773 | 0 |
_tCirculation _gvol. 112 _gno. 19 _gp. 2980-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/CIRCULATIONAHA.104.523324 _zAvailable from publisher's website |
| 999 |
_c15900899 _d15900899 |
||